Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Sysmex Corp (6869 JP): 9MFY26 Revenue Drop on China, Guidance Revised Downwards

Sysmex Corp (6869 JP): The US Tariff Wound Would Not Be Deep Enough

Sysmex Corp (6869 JP): Forex to Take Some Sheen Away off Growth in FY26; Japan Still Remains Key

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sysmex-corp" target="_blank" data-smartkarma-citation="entities:19333:1" rel="noopener">Sysmex Corp (6869 JP)</a> has reported stellar performance for Q1FY27, with double-digit growth across key parameters. Revenue increased 24% YoY to ¥131B, mainly driven by hematology sales.</li>
<li>Challenging market environment continues in China, with the region reporting 34% YoY decline in revenue on a local currency basis. However, this remains in-line with initial assumptions.</li>
<li>In addition to strong business progress in the Americas, taking into account recent foreign exchange trends, Sysmex revised upward its earnings forecasts for H1 and FY27.</li>
</ul>



Sysmex Corp (6869 JP) has reported stellar performance for Q1FY27, with double-digit growth across key parameters. Revenue increased 24% YoY to ¥131B, mainly driven by hematology sales.
Challenging market environment continues in China, with the region reporting 34% YoY decline in revenue on a local currency basis. However, this remains in-line with initial assumptions.
In addition to strong business progress in the Americas, taking into account recent foreign exchange trends, Sysmex revised upward its earnings forecasts for H1 and FY27.


Sysmex Corp (6869 JP): Hematology Drives Robust 1Q Performance and Guidance Raise; What Lies Ahead